Pasithea Therapeutics
KTTA
4 hedge funds and large institutions have $1.26M invested in Pasithea Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.16% more ownership
Funds ownership: 0% → 0.16% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$1.21M |
| 2 |
TSS
Two Sigma Securities
New York
|
+$31.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.58K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $1.22M | +$1.21M | +20,000 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $32K | +$31.6K | +522 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $10K | +$10K | +165 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6K | +$5.58K | +92 | New |
|
KTTA Hedge Fund Activity: Q3 2021 in Review
4 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2021, worth a combined $1.26M.
Buyers outnumbered sellers: 4 funds opened new KTTA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $1.21M.
- 4 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $1.26M of Pasithea Therapeutics stock for Q3 2021.
- 4 funds opened new Pasithea Therapeutics positions in Q3 2021 and 0 closed out, a net change of +4 holders.
- The largest Pasithea Therapeutics buyer in Q3 2021 was Kepos Capital, an estimated $1.21M added.
Based on aggregated 13F filings for Q3 2021.